Novartis IP definition

Novartis IP means, collectively, Novartis Know-How and Novartis Patent Rights.
Novartis IP shall have the meaning ascribed in Article 8.1(g) hereof.
Novartis IP. Novartis IP means the Intellectual Property relating to the Novartis Anti-VEGF Products and the Pre-Filled Syringe that is Controlled by Novartis as of the Effective Date or thereafter during the Term, that is reasonably necessary or useful for the Development, Manufacture or Commercialization of a Product in the Field. The term Novartis IP shall not include the Novartis Collaboration IP or Novartis’ rights in the Joint Collaboration IP.

Examples of Novartis IP in a sentence

  • The manufacture, use or sale of the Product by Novartis or the use of the Trademarks and any other Novartis IP used to promote the Product in the Territory for the sale of the Product do not and to Novartis’ knowledge will not infringe any valid rights of any third party including inter alia intellectual property rights (other than such rights as to which Novartis is directly or indirectly licensed).

  • Any licenses associated with the Novartis IP are valid and binding and are enforceable in accordance with their respective terms, and there are no material breaches or defaults thereunder.

  • Novartis shall use commercially reasonable efforts to (i) cause the counterparty to any such agreements to perform under such agreements and (ii) retain its rights to the Novartis IP to the extent necessary to discharge its obligations under this Agreement with respect to the Products, including, without limitation, granting the rights and licenses granted to Reliant under this Agreement.

  • Novartis shall comply with, and shall cause its Affiliates to comply in all material respects with the terms of any agreements through which Novartis or its Affiliates are granted rights or licenses relating to the Novartis IP, except where the failure to so comply with such agreements could not reasonably be expected to adversely effect Reliant’s ability to perform its obligations under this Agreement.

  • Novartis shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to any and all Novartis IP and any other Inventions that is conceived or first reduced to practice by employees of, or consultants to, Novartis, alone or jointly with any Third Party, without the use in any material respect of any BeiGene IP or Joint IP.

  • Except as expressly provided in Section 2.2, and subject to Section 2.6, all rights in and to the Novartis IP, and Novartis’ and its Affiliates’ interests in Joint IP and any other Patent Rights or Know-How of Novartis and its Affiliates, are hereby retained by Novartis and its Affiliates.

  • BeiGene shall have sole and exclusive ownership of all right, title and interest on a worldwide basis in and to any and all BeiGene IP and any other Inventions that is conceived or first reduced to practice by employees of, or consultants to, BeiGene, alone or jointly with any Third Party, without the use in any material respect of any Novartis IP or Joint IP.

  • Novartis shall have the sole right to Handle Patent Rights included in the Novartis IP or the Novartis Collaboration IP worldwide (“Novartis Patent Rights”).

  • Nothing in this Agreement shall affect Spark’s ownership of the Spark IP existing as the Effective Date or Novartis’ ownership of the Novartis IP existing as of the Effective Date, which in each case shall remain owned by the Party having such rights.

  • Subject to the provisions of any Third Party license agreement under which Novartis’ rights in Novartis IP are granted, Novartis shall have the sole right, but not the obligation, to initiate a suit or take other appropriate action that it believes is reasonably required to protect (i.e., prevent or ▇▇▇▇▇ actual or threatened infringement, unauthorized use, or violation of) or otherwise enforce any of the Novartis IP worldwide.


More Definitions of Novartis IP

Novartis IP means Intellectual Property in any country of the world that is: (i) Controlled by Novartis as of the Effective Date or thereafter during the Term; and (ii) conceived, reduced to practice, authored, created, developed or in-licensed by Novartis in the performance of its obligations under this Agreement or used by Novartis in exercise of Novartis’ rights under this Agreement in the Novartis Territory; and (iii) reasonably necessary or useful for the Development or Commercialization of Luxturna in the Field. The term Novartis IP shall not include Novartis’ rights in the Joint IP.